S1700 SGLT-2 Inhibitors: A Therapeutic Avenue for Non-Alcoholic Fatty Liver Disease, Demonstrating Improvements in Imaging Biomarkers and Histological Features, Including Reduced Hepatic Fibrosis, and Ballooning